July 22, 2025 a 01:00 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc., a global leader in biopharmaceuticals, has showcased a resilient performance throughout recent months. Analyst ratings display a rather conservative stance, with a notable emphasis on 'Hold' recommendations. As the market navigates ongoing challenges and opportunities in the healthcare sector, understanding these ratings could prove crucial for investors seeking stability and long-term growth.
Historical Stock Grades
The following table presents the latest analyst ratings for Pfizer as of July 1, 2025. The majority of analysts are adopting a 'Hold' stance, indicating a general sentiment of neutrality towards the stock.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, the analysis reveals a stabilization in the number of ratings with a predominant 'Hold' consensus. The overall count of recommendations has slightly decreased, with minimal shifts among other categories. Noteworthy trends include:
- A consistent holding pattern with declining 'Strong Buy' recommendations.
- A steady increase in 'Hold' ratings, suggesting cautious investor sentiment.
- Limited movement in 'Sell' and 'Strong Sell' recommendations, indicating stability in outlook.
Percentage Trends
Percentage trends over the past year reflect substantive shifts among analyst ratings. Key takeaways include:
- Reduction in 'Strong Buy' ratings from 14% in 2024-11 to nearly 7% in 2025-07.
- Persistent increase in 'Hold' ratings, peaking at 68% recently.
- 'Buy' recommendations remain consistent, yet with little fluctuation observed.
- Overall ratings depict a market with cautious optimism as buying eagerness fades.
These trends underline a noted shift towards conservative evaluation amidst uncertain market conditions, emphasizing prudence over aggressive expansion.
Latest Analyst Recommendations
The recent list of analyst recommendations provides valuable insights into market sentiment. This table reflects the latest shifts in opinion for Pfizer stock:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-30 | Neutral | Neutral | UBS |
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2025-04-08 | Neutral | Neutral | UBS |
| 2025-03-18 | Buy | Buy | Guggenheim |
| 2025-03-12 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
The table below highlights the most recent notable changes in analyst opinions, showcasing significant shifts in their perspectives regarding Pfizer's stock:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The data reflects a stabilizing, yet cautious market perspective on Pfizer's stock. While 'Hold' ratings are prevalent, the shift from 'Strong Buy' indicates a tempered enthusiasm. The prevailing neutral stance implies cautious optimism, with most analysts opting for stability amid market flux. These findings suggest a sentiment of caution, yet notable confidence in Pfizer's longer-term business strategy and its ongoing developments in biopharmaceutical innovation.
Conclusion
Pfizer Inc.'s current analyst ratings highlight a trend of cautious optimism, characterized by a dominant 'Hold' sentiment. The reduction in 'Strong Buy' ratings and the persistence of 'Hold' evaluations signify market hesitancy amid shifting dynamics. While short-term growth may appear subdued, Pfizer's strategic position in innovative healthcare solutions remains strong, offering potential for sustained long-term growth. Consequently, investors might contemplate balancing the stock in a diversified portfolio to capture future opportunities while mitigating risks.